Swiss Fine Chemicals
(0 item) - CHF0.00

You have no items in your shopping cart.

  • Swiss fine chemicals company
  • Swiss fine chemicals company
  • Swiss fine chemicals company
  • Swiss fine chemicals company
  • Swiss fine chemicals company
  • Swiss fine chemicals company
  • Swiss fine chemicals company

SpiroChem - Your innovative partner in the journey ahead

SpiroChem is a Swiss fine chemicals company, headquartered in Basel, Switzerland.

We are a fine chemicals company specialized in the design, synthesis, production and commercialization of novel building blocks for use in drug discovery.
With cutting-edge know-how in drug design and proprietary process chemistry technologies, SpiroChem is the partner of choice for pharmaceutical, agrochemical, and life science companies of all sizes. Our clients are located worldwide, including many of the top pharma companies.

Our unique repertoire of molecular fragments is designed to help medicinal chemists accelerate drug discovery and lead optimization programs in the Life Science sector. In particular, our products and associated services allow scientists and medicinal chemists to improve ADME properties and design better drugs for tomorrow.

Spirochem AG Mission

Our Mission:

To develop cutting-edge concepts for discovery chemistry;

To accelerate your medicinal chemistry programs;

Spirochem AG Vision

Our Vision:

To be the leading R&D partner for chemical innovation and services in the life-science industry;

SpiroChem is the world-leading chemicals company on the concept of bioisosterism.

In particular, we have established a leadership position on the highly sought-after field of conformationally-restricted molecules and the concept of bioisosterism. We offer bioisosteric replacements for a variety of functional groups, such as acids, amides, heterocycles, lipophilic groups and benzenes. In particular, we have developed scalable processes to bicyclo[1.1.1]pentane scaffolds and we can also provide many oxetanes, spirocycles and cubanes on scale.

If you are looking for expertise in bicyclo[1.1.1]pentane or any of the above mentioned chemical series, you are at the right place! We offer you expertise, speed, innovation and efficiency; our technology allows the largest diversity, scalability and the shortest lead times!

Utilize our expertise to accelerate your R&D

SpiroChem offers Custom Synthesis Services for the design and the synthesis of your target molecules from milligram to kilogram-scale. We are specialized in the design, synthesis & production of complex small organic molecules & innovative building blocks for use in drug discovery. We can prepare analogs of our own molecules, but we are also leading the chemistry service market on the medium-to-high complexity chemistry segment.

Our personalized services to our clients include:

1) supporting lead optimization programs to quickly improve ADME properties of drug candidates

2) entering into new chemical space and expand their IP-portfolio and strengthen their IP position

3) high-performing knowledgeable teams and dedicated equipped lab space

4) highly competent Scientific Consultancy (including access to SpiroChem advisors – Prof. Erick M. Carreira, Dr. Thomas Fessard, Dr. Florent Beaufils and Prof. David Sarlah)


“Teamwork is our strength: it is all about chemists interacting with fellow chemists”

We have ongoing collaborations with key academic groups and technology companies worldwide. To accelerate the penetration of our products worldwide, we have also established a strong network of distributors, so depending on our clients’ policy, they can buy directly from us or from their usual chemicals suppliers.

SpiroChem AG and the SpiroTeam are the laureates of several competitions and recipient of awards, including the IMD-Start-up award, Venture Leaders China and the EFMC prize for Young Medicinal Chemist in Industry. SpiroChem as a fine chemicals company is also a recipient of two CTI grants.

SpiroChem - Tailor-made molecules to design the drugs of tomorrow.

 

Thomas

Thomas Fessard, PhD - CEO

Thomas studied chemistry in France (ENSC, Montpellier) and the UK (UMIST, Manchester) and obtained a PhD degree from the university of Nottingham, UK.

After research appointments at the School of Pharmacy in Nottingham and ETH Zürich, Thomas joined Lipideon Biotechnology AG in 2007. As Head of the Drug Discovery and Chemistry, he lead a multi-disciplinary team that discovered a candidate for pre-clinical investigation (Non-Systemic Cholesterol Absorption Inhibitor).

In 2011, Thomas co-founded SpiroChem AG, Swiss fine chemicals company and serves as CEO of the company.

Thomas has several years of experience in the management of R&D projects, including medicinal chemistry, design of innovative building blocks for drug discovery and development of new process routes.

 

Florent

Florent Beaufils, PhD – COO

Florent has over 10 years of accomplishments in the Pharma/Biotech industry. His professional experience includes the discovery, process and preclinical development of various protein kinase inhibitors for the treatment of cancer (PQR309, FDA Orphan Drug Designation in 2016) and CNS disorders (PQR620), and a successful technology transfer (2009) with New England Biolabs (SNAP-tag®, CLIP-tag™).

Florent received his Ph.D. in Organic Chemistry at the University of Bern in 2004, and carried out postdoctoral work on total synthesis with Alois Fürstner at the Max Planck Institute für Kohlenforschung in 2005. He was Head of Chemistry and Quality Control at Covalys Biosciences AG (Switzerland) (2005 - 2009), Senior Researcher at the Department of Biomedicine of the University of Basel (2009 - 2012) and Deputy Head of Chemistry at PIQUR Therapeutics AG (2012 - 2016).

Florent is co-author of numerous high impact scientific publications and co-inventor of 10 patents in the areas of drug discovery, process development and biological research.

Peter

Peter Harboe-Schmidt, MSc, MBA (IMD) (Chairman)

Peter brings a wealth of start-up and industry experience from small and large biotech companies. He was co-founder and acting CEO of Xigen Pharma and was previously head of Business Development at Modex Therapeutics, playing a key role for its IPO on the Swiss Stock exchange. Prior to this, he was Head of Market Research and Business Planning with Amgen Europe where he led a pan-European market research organization. Before that he worked in various managerial positions with DuPont de Nemours in manufacturing, sales and Business Development. As a CTI Startup coach, he has coached the founders and CEOs of over 30 Swiss life science companies.

 

Erick

Prof. Erick M. Carreira, PhD

Erick obtained a B.S. degree from the University of Illinois at Urbana­Champaign and a Ph.D. degree from Harvard University. After carrying out postdoctoral work with Peter Dervan at the California Institute of Technology through late 1992, he joined the faculty at the same institution and was promoted to the rank of full professor. Since 1998, he has been full professor of Organic Chemistry at the ETH Zürich. He is the recipient of many academic and industrial awards. His research program focuses on the asymmetric synthesis of biologically active, stereochemically complex, natural products.

Recent advances from the Carreira group in the design of novel building blocks for drug discovery have had a high impact in the pharmaceutical industry and are the basis of the foundation of SpiroChem AG, Swiss fine chemicals company.

 

Thomas

Thomas Fessard, PhD

Thomas studied chemistry in France (ENSC, Montpellier) and the UK (UMIST, Manchester) and obtained a PhD degree from the university of Nottingham, UK.

After research appointments at the School of Pharmacy in Nottingham and ETH Zürich, Thomas joined Lipideon Biotechnology AG in 2007. As Head of the Drug Discovery and Chemistry, he lead a multi-disciplinary team that discovered a candidate for pre-clinical investigation (Non-Systemic Cholesterol Absorption Inhibitor).

In 2011, Thomas co-founded SpiroChem AG, Swiss fine chemicals company and serves as CEO of the company.

Thomas has several years of experience in the management of R&D projects, including medicinal chemistry, design of innovative building blocks for drug discovery and development of new process routes.

 

Anthony

Dr. Anthony D. Baxter, PhD

Dr. Anthony Baxter is a serial entrepreneur and past CEO of several successful science-based CROs: Cyprotex plc, sold (2016) to Evotec (58 mio £) | Argenta Discovery, sold (2014) to CRL (30 mio £).

He has held C-level and Chairman posts at Oxford Asymmetry Ltd, sold (2000) to Evotec (360 mio £), deltaDOT Ltd, Glythera Ltd, DNAmeIT Ltd amongst others.

Before becoming an entrepreneur, Tony worked as a medicinal chemist with 13 years senior level experience with GSK (1983-1990) and Ciba-Geigy UK (now Novartis, 1990-1995).

Tony graduated from the University of Manchester in Salford, UK (MSc, PhD)